MARIETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
Friday, September 6, 2024
New York, NY
Lake Street 8th Annual Big8 Best Ideas Growth Conference
Thursday, September 12, 2024
Minneapolis, MN
2024 Cantor Global Healthcare Conference
Webcast (8:00 AM ET): Click here to access
Wednesday, September 18, 2024
New York, NY
Investors interested in meeting with senior management at these events may contact their respective Morgan Stanley, Lake Street or Cantor representative.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.40 |
| Daily Change: | -0.15 -2.29 |
| Daily Volume: | 76,557 |
| Market Cap: | US$940.480M |
May 05, 2025 April 10, 2025 February 27, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
